The company best known for its Cologuard colon cancer screening test posted a loss of $86 million, or $0.45 per share, on revenue of $878.4 million.
Exact Sciences misses Q4 expectations for earnings, beats for revenue
The company best known for its Cologuard colon cancer screening test posted a loss of $86 million, or $0.45 per share, on revenue of $878.4 million.